Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma

Teruo Inamoto; Ryo Sato; Yuto Matsushita; Taizo Uchimoto; Ko Nakamura; Kazumasa Komura; Kazuki Nishimura; Yusuke Yano; Kyosuke Nishio; Shoko Kinoshita; Tatsuo Fukushima; Tomohisa Matsunaga; Keita Nakamori; Takeshi Tsutsumi; Takuya Tsujino; Hirofumi Uehara; Kiyoshi Takahara; Hideaki Miyake; Haruhito Azuma

doi:10.21873/cdp.10226

Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma

Teruo Inamoto, Ryo Sato, Yuto Matsushita, Taizo Uchimoto, Ko Nakamura, Kazumasa Komura, Kazuki Nishimura, Yusuke Yano, Kyosuke Nishio, Shoko Kinoshita, Tatsuo Fukushima, Tomohisa Matsunaga, Keita Nakamori, Takeshi Tsutsumi, Takuya Tsujino, Hirofumi Uehara, Kiyoshi Takahara, Hideaki Miyake, Haruhito Azuma

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

1 被引用数 (Scopus)

抄録

Background/Aim: The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). Patients and Methods: The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. Results: The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation.

本文言語	英語
ページ（範囲）	370-376
ページ数	7
ジャーナル	Cancer Diagnosis and Prognosis
巻	3
号	3
DOI	https://doi.org/10.21873/cdp.10226
出版ステータス	出版済み - 2023
外部発表	はい

All Science Journal Classification (ASJC) codes

癌研究
腫瘍学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.21873/cdp.10226

他のファイルとリンク

フィンガープリント

「Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Inamoto, T., Sato, R., Matsushita, Y., Uchimoto, T., Nakamura, K., Komura, K., Nishimura, K., Yano, Y., Nishio, K., Kinoshita, S., Fukushima, T., Matsunaga, T., Nakamori, K., Tsutsumi, T., Tsujino, T., Uehara, H., Takahara, K., Miyake, H., & Azuma, H. (2023). Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma. Cancer Diagnosis and Prognosis, 3(3), 370-376. https://doi.org/10.21873/cdp.10226

@article{4cee35900b5740679bdfd110d1395735,

title = "Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma",

abstract = "Background/Aim: The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). Patients and Methods: The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. Results: The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation.",

keywords = "pembrolizumab, prognosis, Response, therapy switch",

author = "Teruo Inamoto and Ryo Sato and Yuto Matsushita and Taizo Uchimoto and Ko Nakamura and Kazumasa Komura and Kazuki Nishimura and Yusuke Yano and Kyosuke Nishio and Shoko Kinoshita and Tatsuo Fukushima and Tomohisa Matsunaga and Keita Nakamori and Takeshi Tsutsumi and Takuya Tsujino and Hirofumi Uehara and Kiyoshi Takahara and Hideaki Miyake and Haruhito Azuma",

note = "Publisher Copyright: {\textcopyright} 2023 International Institute of Anticancer Research.",

year = "2023",

doi = "10.21873/cdp.10226",

language = "English",

volume = "3",

pages = "370--376",

journal = "Cancer Diagnosis and Prognosis",

issn = "2732-7787",

publisher = "International Institute of Anticancer Research",

number = "3",

}

Inamoto, T, Sato, R, Matsushita, Y, Uchimoto, T, Nakamura, K, Komura, K, Nishimura, K, Yano, Y, Nishio, K, Kinoshita, S, Fukushima, T, Matsunaga, T, Nakamori, K, Tsutsumi, T, Tsujino, T, Uehara, H, Takahara, K, Miyake, H & Azuma, H 2023, 'Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma', Cancer Diagnosis and Prognosis, vol. 3, no. 3, pp. 370-376. https://doi.org/10.21873/cdp.10226

TY - JOUR

T1 - Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma

AU - Inamoto, Teruo

AU - Sato, Ryo

AU - Matsushita, Yuto

AU - Uchimoto, Taizo

AU - Nakamura, Ko

AU - Komura, Kazumasa

AU - Nishimura, Kazuki

AU - Yano, Yusuke

AU - Nishio, Kyosuke

AU - Kinoshita, Shoko

AU - Fukushima, Tatsuo

AU - Matsunaga, Tomohisa

AU - Nakamori, Keita

AU - Tsutsumi, Takeshi

AU - Tsujino, Takuya

AU - Uehara, Hirofumi

AU - Takahara, Kiyoshi

AU - Miyake, Hideaki

AU - Azuma, Haruhito

PY - 2023

Y1 - 2023

N2 - Background/Aim: The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). Patients and Methods: The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. Results: The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation.

AB - Background/Aim: The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). Patients and Methods: The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. Results: The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation.

KW - pembrolizumab

KW - prognosis

KW - Response

KW - therapy switch

UR - http://www.scopus.com/inward/record.url?scp=85208024950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85208024950&partnerID=8YFLogxK

U2 - 10.21873/cdp.10226

DO - 10.21873/cdp.10226

M3 - Article

AN - SCOPUS:85208024950

SN - 2732-7787

VL - 3

SP - 370

EP - 376

JO - Cancer Diagnosis and Prognosis

JF - Cancer Diagnosis and Prognosis

IS - 3

ER -